GlassScriptPhysician profile
Tara N Hendrix
NPI 1467505958
$2,226.10
in general payments reported to CMS, 2019-2025
21 companies · $696 in 2025
The $696 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $164 · 2023: $336 · 2024: $657 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.01 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $413.48 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $279.19 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $209.42 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $185.60 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $106.22 | 2021-2025 | |
| Exact Sciences Corporation | $90.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $72.83 | 2024 | |
| Verona Pharma, INC. | $63.17 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $56.54 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.85 | 2024-2025 | Caplyta |
| Abbvie INC. | $33.36 | 2023 | |
| Amgen INC. | $32.74 | 2021 | |
| Mylan Specialty L.P. | $27.05 | 2021-2022 | |
| Amarin Pharma, INC. | $24.23 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.23 | 2025 | Gemtesa |
| Abbott Laboratories | $22.97 | 2025 | Freestyle Libre 3 |
| Nevro Corp. | $22.61 | 2023 | Senza |
| Phathom Pharmaceuticals, INC. | $20.63 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $17.46 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.98 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.